Skip Nav Destination
Issues
1 January 2007
-
Cover Image
Cover Image
SMAD4 is a tumor suppressor gene whose inactivation by the various mechanisms frequently occurs in association with malignant progression. Cytoplasmic and nuclear expression levels of SMAD4 are increased in both low-grade and high-grade dysplasia but are gradually reduced as dysplasia progresses to gastric adenocarcinoma. This figure shows strong cytoplasmic and nuclear staining of SMAD4 in stage I of gastric carcinoma, but SMAD4 is gradually reduced as the carcinoma develops to subsequent stages, possibly owing to a modified two-hit model of tumor suppressor genes as proposed in the article. For more details, please see Wang et al. on page 102 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
The Biology Behind
Molecular Pathways
Review
Human Cancer Biology
Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration[?Q1: Running head: UCHL1, a Biomarker of RCC. Short title OK?Q1]
Barbara Seliger; Alla Fedorushchenko; Walburgis Brenner; Angelika Ackermann; Derek Atkins; Samir Hanash; Rudolf Lichtenfels
Radiation Effects on Development of HER2-Positive Breast Carcinomas
Fabio Castiglioni; Monica Terenziani; Maria Luisa Carcangiu; Raffaella Miliano; Piera Aiello; Lorenzo Bertola; Tiziana Triulzi; Patrizia Gasparini; Tiziana Camerini; Gabriella Sozzi; Franca Fossati-Bellani; Sylvie Ménard; Elda Tagliabue
Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis
Sonja Loges; Henning Clausen; Uta Reichelt; Michael Bubenheim; Andreas Erbersdobler; Paulus Schurr; Emre Yekebas; Gunter Schuch; Jakob Izbicki; Klaus Pantel; Carsten Bokemeyer; Walter Fiedler
Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis
Kay Savage; Maryou B.K. Lambros; David Robertson; Robin L. Jones; Chris Jones; Alan Mackay; Michelle James; Jason L. Hornick; Emilio M. Pereira; Fernanda Milanezi; Christopher D.M. Fletcher; Fernando C. Schmitt; Alan Ashworth; Jorge S. Reis-Filho
Imaging, Diagnosis, Prognosis
Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors
Narasimhan P. Agaram; Peter Besmer; Grace C. Wong; Tianhua Guo; Nicholas D. Socci; Robert G. Maki; Diann DeSantis; Murray F. Brennan; Samuel Singer; Ronald P. DeMatteo; Cristina R. Antonescu
Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy
Luca Arcaini; Sara Burcheri; Andrea Rossi; Cristiana Pascutto; Francesco Passamonti; Ercole Brusamolino; Marco Paulli; Ester Orlandi; Maurizio Buelli; Piera Viero; Marco Lucioni; Francesca Montanari; Michele Merli; Sergio Cortelazzo; Mario Lazzarino
Nonsynonymous Coding Single-Nucleotide Polymorphisms Spanning the Genome in Relation to Glioblastoma Survival and Age at Diagnosis
Margaret Wrensch; Alex McMillan; John Wiencke; Joe Wiemels; Karl Kelsey; Joe Patoka; Hywel Jones; Victoria Carlton; Rei Miike; Jennette Sison; Michelle Moghadassi; Michael Prados
Cancer Therapy: Clinical
Expression of Cellular FLICE Inhibitory Protein, Caspase-8, and Protease Inhibitor-9 in Ewing Sarcoma and Implications for Susceptibility to Cytotoxic Pathways
Alfons S.K. de Hooge; Dagmar Berghuis; Susy Justo Santos; Esther Mooiman; Salvatore Romeo; J. Alain Kummer; R. Maarten Egeler; Maarten J.D. van Tol; Cornelis J.M. Melief; Pancras C.W. Hogendoorn; Arjan C. Lankester
Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer
Monica N. Fornier; Andrew D. Seidman; Diana Lake; Gabriella D'Andrea; Jacqueline Bromberg; Mark Robson; Catherine Van Poznak; Katherine S. Panageas; Marietta Atienza; Larry Norton; Clifford Hudis
Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen
Aman U. Buzdar; Vicente Valero; Nuhad K. Ibrahim; Deborah Francis; Kristine R. Broglio; Richard L. Theriault; Lajos Pusztai; Marjorie C. Green; Sonja E. Singletary; Kelly K. Hunt; Aysegul A. Sahin; Francisco Esteva; William F. Symmans; Michael S. Ewer; Thomas A. Buchholz; Gabriel N. Hortobagyi
Cancer Therapy: Preclinical
The Combi-Targeting Concept: In vitro and In vivo Fragmentation of a Stable Combi-Nitrosourea Engineered to Interact with the Epidermal Growth Factor Receptor while Remaining DNA Reactive
Qiyu Qiu; Juozas Domarkas; Ranjita Banerjee; Nuria Merayo; Fouad Brahimi; James P. McNamee; Bernard F. Gibbs; Bertrand J. Jean-Claude
Cancer Susceptibility and Prevention
Advertisement